-
1
-
-
0242456086
-
Scope of worldwide hepatitis C problem
-
Brown R.S., and Gaglio J.P. Scope of worldwide hepatitis C problem. Liver Transpl 9 11 (2003) S10-S13
-
(2003)
Liver Transpl
, vol.9
, Issue.11
-
-
Brown, R.S.1
Gaglio, J.P.2
-
2
-
-
1442308277
-
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
-
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 140 5 (2004) 370-381
-
(2004)
Ann Intern Med
, vol.140
, Issue.5
, pp. 370-381
-
-
Zeuzem, S.1
-
3
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial
-
Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 9286 (2001) 958-965
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
4
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
-
(2002)
N Engl J Med
, vol.347
, Issue.13
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
5
-
-
0034619946
-
Peginterferon alfa-2a in patients with chronic hepatitis C
-
Zeuzem S., Feinmann S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343 23 (2000) 1666-1672
-
(2000)
N Engl J Med
, vol.343
, Issue.23
, pp. 1666-1672
-
-
Zeuzem, S.1
Feinmann, S.V.2
Rasenack, J.3
-
6
-
-
1542378867
-
Peginterferon-alfa-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose
-
Hadziyannis S., Sette Jr. H., Morgan T.R., et al. Peginterferon-alfa-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 40 5 (2004) 346-355
-
(2004)
Ann Intern Med
, vol.40
, Issue.5
, pp. 346-355
-
-
Hadziyannis, S.1
Sette Jr., H.2
Morgan, T.R.3
-
7
-
-
0037371144
-
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
-
Berg T., Sarrazin C., Herrmann E., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 3 (2003) 600-609
-
(2003)
Hepatology
, vol.37
, Issue.3
, pp. 600-609
-
-
Berg, T.1
Sarrazin, C.2
Herrmann, E.3
-
8
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 3 (2005) 425-433
-
(2005)
J Hepatol
, vol.43
, Issue.3
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
-
9
-
-
0031924165
-
Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
-
Zeuzem S., Lee J.H., Franke A., et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27 (1998) 1149-1156
-
(1998)
Hepatology
, vol.27
, pp. 1149-1156
-
-
Zeuzem, S.1
Lee, J.H.2
Franke, A.3
-
10
-
-
0041822106
-
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
-
Davis G.L., Wong J.B., McHutchison J., et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 3 (2003) 645-652
-
(2003)
Hepatology
, vol.38
, Issue.3
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.3
-
11
-
-
0033802570
-
Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
-
Sarrazin C., Teuber G., Kokka R., et al. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 32 4 Pt 1 (2000) 818-823
-
(2000)
Hepatology
, vol.32
, Issue.4 PART 1
, pp. 818-823
-
-
Sarrazin, C.1
Teuber, G.2
Kokka, R.3
-
12
-
-
33747048398
-
HCV RNA detection by TMA during the Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
-
HALT-C Trial Group
-
Morishima C., Morgan T.R., Everhart J.E., et al., HALT-C Trial Group. HCV RNA detection by TMA during the Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 44 2 (2006) 360-367
-
(2006)
Hepatology
, vol.44
, Issue.2
, pp. 360-367
-
-
Morishima, C.1
Morgan, T.R.2
Everhart, J.E.3
-
13
-
-
30044437827
-
American Gastroenterological Association medical position statement on the management of hepatitis C
-
Dienstag J.L., and McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130 1 (2006) 225-230
-
(2006)
Gastroenterology
, vol.130
, Issue.1
, pp. 225-230
-
-
Dienstag, J.L.1
McHutchison, J.G.2
-
14
-
-
1842479859
-
Diagnosis, management, and treatment of hepatitis C
-
Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 4 (2004) 1147-1171
-
(2004)
Hepatology
, vol.39
, Issue.4
, pp. 1147-1171
-
-
Strader, D.B.1
Wright, T.2
Thomas, D.L.3
-
15
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem S., Buti M., Ferenci P., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 1 (2006) 97-103
-
(2006)
J Hepatol
, vol.44
, Issue.1
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
-
16
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
-
Jensen D.M., Morgan T.R., Marcellin P., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 5 (2006) 954-960
-
(2006)
Hepatology
, vol.43
, Issue.5
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
-
17
-
-
34250881946
-
24 Week treatment regimen with peginterferon-alpha-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 'super-responders.'
-
Ferenci P., Bergholz U., Laferl H., et al. 24 Week treatment regimen with peginterferon-alpha-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 'super-responders.'. J Hepatol 44 Suppl 2 (2006) S6
-
(2006)
J Hepatol
, vol.44
, Issue.SUPPL. 2
-
-
Ferenci, P.1
Bergholz, U.2
Laferl, H.3
-
18
-
-
21844477610
-
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
-
Zeuzem S., Pawlotsky J.M., Lukasiewicz E., et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 43 2 (2005) 250-257
-
(2005)
J Hepatol
, vol.43
, Issue.2
, pp. 250-257
-
-
Zeuzem, S.1
Pawlotsky, J.M.2
Lukasiewicz, E.3
-
19
-
-
46749103460
-
Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise "super-responders."
-
Berg T., Weich V., Teuber G., et al. Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise "super-responders.". Hepatology 44 Suppl 1 (2006) 319A
-
(2006)
Hepatology
, vol.44
, Issue.SUPPL. 1
-
-
Berg, T.1
Weich, V.2
Teuber, G.3
-
20
-
-
34447644163
-
Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2A (40 KD) (Pegasys) plus ribavirin (Copegus)
-
Zeuzem S., Fried M.W., Reddy K.R., et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2A (40 KD) (Pegasys) plus ribavirin (Copegus). Hepatology 44 Suppl 1 (2006) 267A
-
(2006)
Hepatology
, vol.44
, Issue.SUPPL. 1
-
-
Zeuzem, S.1
Fried, M.W.2
Reddy, K.R.3
-
21
-
-
46749085258
-
Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (Pegasys) plus ribavirin: improving differentiation between low (lvl) and high baseline viral load (hvl)
-
Zehnter E., Mauss S., John C., et al. Better prediction of SVR in patients with HCV genotype 1 (G1) with peginterferon alfa-2a (Pegasys) plus ribavirin: improving differentiation between low (lvl) and high baseline viral load (hvl). Hepatology 44 Suppl 1 (2006) 328A
-
(2006)
Hepatology
, vol.44
, Issue.SUPPL. 1
-
-
Zehnter, E.1
Mauss, S.2
John, C.3
-
22
-
-
34548017344
-
Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin
-
Berg T., von Wagner M., Hinrichsen H., et al. Definition of a pre-treatment viral load cut-off for an optimized prediction of treatment outcome in patients with genotype 1 infection receiving either 48 or 72 weeks of peginterferon alfa-2a plus ribavirin. Hepatology 44 Suppl 1 (2006) 321A
-
(2006)
Hepatology
, vol.44
, Issue.SUPPL. 1
-
-
Berg, T.1
von Wagner, M.2
Hinrichsen, H.3
-
23
-
-
0038035716
-
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases
-
Buti M., Valdez A., Sanchez-Avila F., et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 37 5 (2003) 1226-1227
-
(2003)
Hepatology
, vol.37
, Issue.5
, pp. 1226-1227
-
-
Buti, M.1
Valdez, A.2
Sanchez-Avila, F.3
-
24
-
-
33645992473
-
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
-
Berg T., von Wagner M., Nasser S., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 4 (2006) 1086-1097
-
(2006)
Gastroenterology
, vol.130
, Issue.4
, pp. 1086-1097
-
-
Berg, T.1
von Wagner, M.2
Nasser, S.3
-
25
-
-
33746564989
-
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
-
TeraViC-4 Study Group
-
Sanchez-Tapias J.M., Diago M., Escartin P., et al., TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 2 (2006) 451-460
-
(2006)
Gastroenterology
, vol.131
, Issue.2
, pp. 451-460
-
-
Sanchez-Tapias, J.M.1
Diago, M.2
Escartin, P.3
-
26
-
-
37749051824
-
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
-
Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46 6 (2007) 1688-1694
-
(2007)
Hepatology
, vol.46
, Issue.6
, pp. 1688-1694
-
-
Pearlman, B.L.1
Ehleben, C.2
Saifee, S.3
-
27
-
-
34250896579
-
Customizing treatment with peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in patients with HCV genotype 1 or 4 infection, interim results of a prospective randomized trial
-
Ferenci P., Laferl H., Scherzer T.-M., et al. Customizing treatment with peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (Copegus) in patients with HCV genotype 1 or 4 infection, interim results of a prospective randomized trial. Hepatology 44 Suppl 1 (2006) 336A
-
(2006)
Hepatology
, vol.44
, Issue.SUPPL. 1
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.-M.3
-
28
-
-
1642328395
-
A 48-week duration of therapy with pegylated interferon-alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus
-
Drusano G.L., and Preston S.L. A 48-week duration of therapy with pegylated interferon-alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 189 (2004) 964-970
-
(2004)
J Infect Dis
, vol.189
, pp. 964-970
-
-
Drusano, G.L.1
Preston, S.L.2
-
29
-
-
2442683905
-
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3
-
Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 40 6 (2004) 993-999
-
(2004)
J Hepatol
, vol.40
, Issue.6
, pp. 993-999
-
-
Zeuzem, S.1
Hultcrantz, R.2
Bourliere, M.3
-
30
-
-
0033914625
-
Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus
-
Neumann A.U., Lam N.P., Dahari H., et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182 (2000) 28-35
-
(2000)
J Infect Dis
, vol.182
, pp. 28-35
-
-
Neumann, A.U.1
Lam, N.P.2
Dahari, H.3
-
31
-
-
10644264391
-
Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
-
Dalgard O., Bjoro K., Hellum K.B., et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40 6 (2004) 1260-1265
-
(2004)
Hepatology
, vol.40
, Issue.6
, pp. 1260-1265
-
-
Dalgard, O.1
Bjoro, K.2
Hellum, K.B.3
-
32
-
-
20544443172
-
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
-
Mangia A., Santoro R., Minerva N., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 25 (2005) 2609-2617
-
(2005)
N Engl J Med
, vol.352
, Issue.25
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
-
33
-
-
23244457832
-
Randomized multicenter study comparing 16 vs. 24 weeks of combination therapy with peginterferon alfa-2a plus ribavirin in patients chronically infected with HCV genotype 2 or 3
-
von Wagner M., Huber M., Berg T., et al. Randomized multicenter study comparing 16 vs. 24 weeks of combination therapy with peginterferon alfa-2a plus ribavirin in patients chronically infected with HCV genotype 2 or 3. Gastroenterology 129 2 (2005) 522-527
-
(2005)
Gastroenterology
, vol.129
, Issue.2
, pp. 522-527
-
-
von Wagner, M.1
Huber, M.2
Berg, T.3
-
34
-
-
34147207791
-
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
-
Yu M.L., Dai C.Y., Huang J.F., et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 4 (2007) 553-559
-
(2007)
Gut
, vol.56
, Issue.4
, pp. 553-559
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
-
35
-
-
34447318385
-
Peginterferon alfa-2A and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
-
Shiffman M.L., Suter F., Bacon B., et al. Peginterferon alfa-2A and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 2 (2007) 124-134
-
(2007)
N Engl J Med
, vol.357
, Issue.2
, pp. 124-134
-
-
Shiffman, M.L.1
Suter, F.2
Bacon, B.3
-
36
-
-
34250852697
-
Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?
-
[abstract no. 8]
-
Willems B., Hadziyannis S.J., Morgan T.R., et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virologic response?. J Hepatol 46 Suppl 1 (2007) S6 [abstract no. 8]
-
(2007)
J Hepatol
, vol.46
, Issue.SUPPL. 1
-
-
Willems, B.1
Hadziyannis, S.J.2
Morgan, T.R.3
|